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The microRNA-1246 promotes metastasis
in non-small cell lung cancer by targeting
cytoplasmic polyadenylation element-binding
protein 4
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Abstract
Background: The microRNAs present a class of non-coding RNAs which are usually implicated in tumor biology.
Recent report has unraveled that a novel member of microRNA family called miR-1246. However, the functional role
and molecular mechanisms of miR-1246 in non-small cell lung cancer (NSCLC) is still elusive.
Methods: Using RT-PCR, luciferase reporter, mRNA microarrays, invasion and migration assays, we investigated the
potential role of miR-1246 in the pathogenesis of NSCLC.
Results: In this study, we showed that miR-1246 markedly promoted NSCLC cell migration and invasion. Meanwhile,
we found that cytoplasmic polyadenylation element binding protein 4 (CPEB4) might be involved and serve as a direct
target of miR-1246 in NSCLC. CPEB4 knockdown substantially enhanced NSCLC migration and invasion resembling the
effect of miR-1246 in NSCLC. CPEB4 is also frequently downregulated in NSCLC and decreased CPEB4 expression
correlated with poor survival.
Conclusions: These results suggested that the miR-1246 may promote cell metastasis by targeting CPEB4. Meanwhile,
the level of CPEB4 could be used as a potential marker in NSCLC patients. Our findings unraveled novel functions of
miR-1246 in lung cancer cells and shed light on NSCLC prognosis.
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Background
Lung cancer is the leading cause of cancer-related mor-
tality worldwide [1]. Lung cancer has been traditionally
subdivided into two principal groups, namely, neuroen-
docrine and non-small cell lung cancer (NSCLC). The
latter type is more common than the former. Cancer
occurs and develops as a complicated result of an accu-
mulation of various endogenous and exogenous effects.
Gene alterations participate in cancer genesis. Alter-
ations in many onco3 genes and tumor suppressor genes
have been reported in lung cancer.
MicroRNAs (miRNA) are small noncoding RNA mole-
cules that primarily serve as a posttranscriptional factor
for gene expression. The miRNA can also function by
base-pairing with the 3’-untranslated region (3’-UTR)
of specific mRNAs [2]. Aberrant expression of miRNAs
are often regarded as biomarkers of biological path-
ways leading to the occurrence of malignancy includ-
ing cancer [3]. Many recent reports have clarified
critical roles for miRNAs in regulating tumor cell inva-
sion, metastasis and migration [4]. It is well known
that miRNAs can participate in numerous biological
processes, such as apoptosis, differentiation and inva-
sion. During tumorigenesis, miRNAs may act either as
an oncogene or a tumor suppressor and contribute to
tumor initiation and progression by regulating specific-
ally matched target genes. The miRNA functions in
tumorigenesis and metastasis by directly targeting on-
cogenes or tumor suppressor genes [5, 6]. Different
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miRNAs may either function as oncogenes or tumor
suppressors [7–10].
Current knowledge of miRNA expression patterns and
function in normal or neoplastic cells is just starting.
The miRNA genes are usually located at fragile sites, as
well as in minimal regions of amplification or common
breakpoint regions, suggesting that miRNAs might be a
new class of genes involved in human tumorigenesis
[11]. For example, miR-15-a and miR-16-1 are fre-
quently deleted and deregulated in patients with B cell
lymphocytic leukemia [12]. Other association between
cancer and miRNAs have been studied, including
reduced expression of miR-143 and miR-145 in colo-
rectal cancers [13] and let-7 in lung cancers [14], high
expression of the precursor miR-155 in Burkitt’s
lymphomas [15], and oncogenic function of miR-17-92
cluster in human B cell lymphomas as well as in lung
cancers [16–18]. Recently, miR-1246 has been identi-
fied through a microRNA array and is potentially im-
portant for tumorigenesis [19]. However, the exact role
of miR-1246 in lung cancer is currently unknown.
In this study, we showed that the expression of
miR-1246 is significantly upregulated in lung cancer
tissues compared with noncancerous tissues. Ectopi-
cally expressed miR-1246 could promote the migra-
tion and invasion of lung cancer cells. Furthermore,
we found that CPEB4 is a direct and functional target
of miR-1246. The expression of CPEB4 is closely corre-
lated with therapeutic outcomes in NSCLC patients.
Methods
Lung cancer samples and cell lines
NSCLC tumor samples and noncancerous adjacent tissues
(NAT, at least 3 cm from the tumor) were obtained from
the surgical specimen archives of the TCM-Integrated
Hospital, Southern Medical University. Our study was
approved by the Ethical Committee of TCM-Integrated
Hospital, Southern Medical University, and every patient
had written informed consent, the study methodologies
conformed to the standards of the Declaration of Helsinki.
All lung cancer cell lines were purchased from Shanghai
Institutes for Biological Sciences, Chinese Academy of
Sciences and cultured according to the instructions (A549,
H460, H1299, H226, H522, H596 and SW-900). Trans-
fection was carried out and evaluated as described pre-
viously [20].
RNA extraction and quantitative real-time PCR
RNA isolation from cells or tissue samples was per-
formed with the mirVana miRNA Isolation Kit (Ambion,
Austin, TX) according to the manufacturer’s protocol.
For RT-PCR detection of miR-1246 oligonucleotide, ma-
ture miR-1246 was reverse- transcribed with specific RT
primers. Reverse transcription was performed using poly
(A)-tailed total RNA and reverse transcription primer
with ImPro-II Reverse Transcriptase (Sigma, Shanghai)
as described previously [21]. The raw data were normal-
ized by U6 small nuclear RNA using TaqMan miRNA
assays (Applied Biosystems, Shanghai).
Vector constructs
The lentivirus vector for miR-1246 expression pWPXL-
miR-1246, the primary miRNA sequence amplified from
normal genomic DNA replaced the green fluorescent
protein fragment of the pWPXL mock vector. In the
luciferase reporter, the wild-type or mutant 3’UTR of
CPEB4 was cloned downstream of the stop codon in the
luciferase. Other potential target genes were cloned in a
similar manner. The sequences of the primary miRNA
and wild-type and mutant 3’ UTR were confirmed by
sequencing.
Lentivirus production and transduction
Virus particles were harvested from HEK 293 T cells
48 h after pWPXL-miR-1246 transfection with the
envelope plasmid pMDG2 and the packaging plasmid
psPAX2 using Lipofectamine 2000. A549 and H226 cells
were infected with recombinant lentivirus-transducing
units and 6 μg/mL polybrene.
Transfection of oligonucleotide
The miRNA mimics and small interfering RNAs (siRNA)
targeting CPEB4 were designed and synthesized by
GenePharma (Shanghai, China). The miR-1246 inhibi-
tor was synthesized by RiboBio (Shanghai, China).
Cells were transfected with mimic or inhibitor using
Lipofectamine 2000, while siRNA transfection was
performed with Lipofectamine RNAi MAX reagents
according to the manufacturer’s instructions (Invitrogen,
Shanghai). The transfection efficiency of miR-1246 mimics
and inhibitors were verified and the inhibition can reach
around 90 % (Additional file 1: Figure S1, A and B). Usu-
ally, after 72 h’ transfection, the cells were collected and
used in further experiments. The sequences for the siRNAs
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Proliferation assay
The proliferation of specific cells was assessed by the
Cell Counting Kit-8 (CCK-8) assay kit (Invitrogen,
Shanghai, China). Approximately 104 cells were seeded
in each well of a 96-well plate, and 10 μL CCK-8 was
added to 90 μL culture medium. After incubation at 37 °C
for 2.5 h, the absorbance was detected at 450 nm and the
OD450 value is correlated with live cell numbers.
Migration and invasion assays
The migration and invasion assays were performed using
a 24-well transwell plate (8-μm pore size, Corning, New
York, USA). 4 × 105 cells suspended in serum-free DMEM
were appended to the upper chamber lined with non-
coated membrane. For invasion assay, chamber inserts
were coated with 2 μg/ml of Matrigel. DMEM contain-
ing 20 % FBS were added to the lower chambers as a
Fig. 1 The miR-1246 is often upregulated in NSCLC and promotes NSCLC cell migration and invasion. a The relative expression of mature
miR-1246 in 50 pairs of NSCLC tissues and their corresponding noncancerous lung tissues were measured using TaqMan real-time PCR
and normalized to U6 snRNA. b CCK-8 assays of A549 and H226 cells were performed every other day after transfection with a miR-1246
mimic or negative control (nc). The data are presented as the mean ± S.E.M. c, d Transwell migration and invasion assays of A549 and
H226 cells stably expressing miR-1246 or mock control. e, f Transwell migration and invasion assays for A549 and H226 cells transfected
with either miR-1246 inhibitor or negative control. Representative images are shown on the left, and quantification is shown on the right.
The results are representative of at least three independent experiments. * p < 0.05, ** p < 0.01, *** p < 0.001
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chemoattractant. After 48 h transfection, the non-
filtered cells were removed from the system with a cotton
swab. Filtered cells located on the lower side of the
chamber were stained with 0.2 % crystal violet (Sigma,
Shanghai) for 0.5 h and then counted with a microscope
(Olympus Corp., Tokyo, Japan).
Fig. 2 miR-1246 downregulates CPEB4 expression by directly targeting its 3’ UTR. a Scheme for the identification of candidate genes combining
microarray assays and a target prediction algorithm. b The mRNA expression levels of the predicted genes in A549 and H226 cells expressing
miR-1246 or vector were evaluated by real-time PCR. c Dual-luciferase activity assays were used to determine the binding potential between
miR-1246 and the 3’ UTR of these candidate genes. Renilla luciferase activity was detected as an internal control. d Western blot assays of the
TRAK2 and CPEB4 protein levels in A549, H226 and HEK 293 T cells. e The sequences of the putative miR-1246-binding site in the wild-type
and mutant (underlined) CPEB4 3’ UTR. f The putative binding sequences for miR-1246 within the human (Has), chimpanzee (Ptr), rhesus (MMl)
and mouse (Mmu) CPEB4 3’ UTR. Seed sequences are indicated as emphasized with shadow. g The relative luciferase activity of luciferase
reporters with wild-type or mutant CPEB4 3’ UTRs was determined in HEK 293 T cells, which were co-transfected with the miR-1246 mimic
or negative control (nc). Renilla luciferase activity was analyzed as an internal control. There is statistical significance between the wild-type group and
the mutant group with miR-1246 transfection. h The protein levels of CPEB4 were determined by western blot assays in H226 cells infected
with miR-1246 or mock vector and H226 cells transfected with the miR-1246 inhibitor or negative control (nc). * p < 0.05, ** p < 0.01, *** p < 0.001
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Luciferase reporter assay
HEK 293 T cells (293 T) were cultured in 96-well plates
and transfected with 50 ng pluc-3’ UTR, 10 ng Renilla and
5 pmol miR-1246 mimic or negative control. After 72 h of
incubation, the luciferase activity was determined using a
dual-luciferase reporter system (Promega, Shanghai).
Immunoblot
Cell lysates were prepared with 10 % SDS-PAGE and
then transferred to the nitrocellulose membrane. The
membrane was incubated with a rabbit anti-CPEB4 poly-
clonal antibody (Sigma, Shanghai), mouse anti-β-actin
(Sigma, Shanghai) or mouse anti-GAPDH monoclonal
antibody (Sigma, Shanghai). The proteins were displayed
with chemi-luminescence reagents (Thermo Scientific,
Hudson, NH, USA).
Immunohistochemical Staining (IHC)
Tumor tissues were fixed in formalin and embedded in
paraffin using the Microm Tissue Embedding Center
(Labequip, Ltd, Markham, Ontario). Then the secretions
were cut (5 μm) and stained with H&E. For immunohis-
tochemical staining, sections were hydrated and blocked
with 4 % H2O2 in water for 15 min. Antigen retrieval
was done with 20 μmol/L citrate buffer (pH 6.0) for
15 min followed by a 20-min cooldown and washed in
TBS with Tween (TTBS: 50 μmol/L Tris–HCl (pH 7.5),
150 mmol/L NaCl, 0.1 % Tween 20). Slides were treated
with Biocare blocking reagent (Biocare Medical) for
15 min to remove nonspecific binding. Slides were
then incubated with antibodies against CPEB4 (Sigma,
Shanghai) for 40 min. Then the slides were washed in
TTBS for 40 min at 20 °C. After washing, the slides
were incubated with antigoat horseradish peroxidase-
conjugated secondary antibodies (BioGenex, San Francisco)
for 40 min at 20 °C.
Statistical analysis
Statistical analysis was carried out using SPSS 16.0 soft-
ware (SPSS Inc.; Chicago, IL, USA). Survival curves were
constructed with the Kaplan-Meier method and com-
pared by log-rank tests. The two-tailed Student t test
was used for the other data analyses. The p values less
than 0.05 were considered significant. Asterisks were
used to represent statistical significance of p values in
some figures, e.g. * p < 0.05, ** p < 0.01, *** p < 0.001.
Results
The miR-1246 is frequently upregulated in NSCLC and
accelerates NSCLC cell migration and invasion
To confirm the expression of miR-1246 in NSCLC, we
detected mature miR-1246 in 50 pairs of NSCLC and
matched noncancerous adjacent tissues by real-time
PCR. The results indicated that miR-1246 expression
was upregulated in NSCLC tissues compared with the
noncancerous tissues (Fig. 1a). A miR-1246 mimic was
transfected into two NSCLC cell lines to determine
whether it could affect cell proliferation and motility.
CCK-8 assays showed that the miR-1246 did not influence
cell growth (Fig. 1b) and transwell assays with or without
Matrigel indicated that miR-1246 markedly induced mi-
gration and invasion in NSCLC cells (Additional file 2:
Figure S2). Next, a miR-1246 expressing lentivirus vector
was constructed to infect A549 and H226 cells which
helps to establish stably transfected cell lines. In transwell
assays, A549 cells overexpressing miR-1246 showed en-
hanced migratory and invasive abilities compared with
vector control (Fig. 1c and d). Similar results were also ob-
served in H226 cells (Fig. 1c and d). We further trans-
fected A549 and H226 cells with miR-1246 inhibitors to
confirm the findings above. The results showed that the
miR-1246 inhibitor could significantly inhibit the migra-
tion and invasion of A549 and H226 cells (Fig. 1e and f).
Taken together, these data demonstrated that miR-1246
can promote NSCLC cell migration and invasion.
The miR-1246 Can downregulate CPEB4 expression by
directly targeting its 3’ UTR
To unravel the detailed molecular mechanisms for miR-
1246 on NSCLC cell migration and invasion, mRNA
microarray assays were performed to identify the genes
that were suppressed by miR-1246 in both A549 and
H226 cells transfected with the miR-1246 mimic. At the
same time, potential targets were predicted using the al-
gorithm TargetScan. By integrating the results of these
Table 1 The possible target genes for miR-1246 in NSCLC cells
Gene Official full name
CPEB4 Cytoplasmic polyadenylation element binding protein 4
ARL2BP ADP-ribosylation factor-like 2 binding protein
KLF12 Kruppel-like factor 12
RPS6KB1 ribosomal protein S6 kinase, 70 kDa, polypeptide 1
UGCGL1 UDP-glucose glycoprotein glucosyltransferase 1
RSBN1 round spermatid basic protein 1
HTR2A 5-hydroxytryptamine (serotonin) receptor 2A
TRAK2 trafficking protein, kinesin binding 2
GPR85 protein-coupled receptor 85
MRPL19 mitochondrial ribosomal protein L19
GALE UDP-galactose-4-epimerase
PDAP1 PDGFA associated protein 1
ARSB Arylsulfatase B
FAM55C family with sequence similarity 55, member C
RBM24 RNA binding motif protein 24
CYLD cylindromatosis (turban tumor syndrome)
PNPO pyridoxamine 5’-phosphate oxidase
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two strategies, 17 genes were found to be plausible tar-
gets (Fig. 2a, Table 1). Real-time PCR, dual-luciferase
reporter and western blot analysis were then performed
to verify whether specific genes were actually targeted
by miR-1246 (Fig. 2b-d). After preliminary screening,
CPEB4 was confirmed as a potential target for miR-
1246 (Fig. 2c and d).
The sequence analysis of the CPEB4 3’ UTR by
TargetScan showed only one plausible site for miR-1246
binding. The site was also highly conserved among
chimpanzees, rhesus, mice and humans (Fig. 2e and f). To
further determine whether CPEB4 is directly regulated by
miR-1246 via common 3’ UTR binding, a luciferase re-
porter containing the wild-type or mutant 3’ UTR of
CPEB4 was constructed. After co-transfection with a miR-
1246 mimic, the luciferase activities were significantly de-
creased in the group co-transfected with wild-type CPEB4
3’ UTR containing vector, while the luciferase activity was
not reduced in the mutant 3’ UTR group (Fig. 2g). This
result suggests that miR-1246 binds to the 3’ UTR of
CPEB4 via the predicted binding site.
In addition, immunoblots also showed that transfection
with miR-1246 can result in decreased CPEB4 expression
in H226 cells (Fig. 2h). Conversely, the miR-1246 inhibitor
Fig. 3 CPEB4 is often reduced in NSCLC and contributes to the low overall survival of NSCLC patients. a Immunohistochemical staining of CPEB4
in NSCLC tissues and noncancerous adjacent tissues. Two cases were shown. NAT: noncancerous adjacent tissue. b The survival curves are shown
for low or high CPEB4 expression level (p < 0.01). The statistical analyses of cases in groups were performed with the χ2 test and Kaplan-Meier
plots. * p < 0.05, ** p < 0.01, *** p < 0.001
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can increase the amount of CPEB4 (Fig. 2h). Collectively,
these results indicated that miR-1246 could negatively
modulate CPEB4 expression by directly targeting its 3’
UTR.
CPEB4 is usually reduced in NSCLC
Previous reports indicated that CPEB4 plays a role in regu-
lating translation, meiotic division and mitosis [22, 23].
However, the expression of CPEB4 in NSCLC remains un-
known. The protein levels of CPEB4 were determined with
IHC staining. The CPEB4 expression was relatively high in
noncancerous adjacent tissues. In contrast, CPEB4 staining
was relatively weak in NSCLC samples (Fig. 3a). Notably,
the intrinsic CPEB4 expression exhibited close correlation
with the overall survival of NSCLC patients (Fig. 3b).
There was no correlation between CPEB4 levels and other
clinicopathological factors such as age, sex and stage
(Table 2). Taken together, these data suggested that the
CPEB4 level was frequently downregulated in NSCLC, and
its expression substantially affected NSCLC prognosis.
The miR-1246 functions via reducing CPEB4 level
in NSCLC
To further clarify the effects of CPEB4 in NSCLC cells,
siRNAs against CPEB4 were intricately designed and
transfected into 293 T cells. The knockdown efficiency
of three constructs was first verified and the results
showed that specific CPEB4 siRNAs could efficiently
reduce CPEB4 transcripts (Fig. 4a). The mRNA and
protein levels of CPEB4 were markedly decreased, particu-
larly in the si-CPEB4-1 group (Fig. 4a, b). Therefore, si-
CPEB4-1 was used in further analysis. A549 cells were
transfected with siRNAs and then subjected to transwell
assays. The result showed that A549 cells transfected with
CPEB4 siRNA exhibited elevated migration and invasion
(Fig. 4c). These results suggested that CPEB4 might be a
direct target of miR-1246 in NSCLC.
We next attempted to determine whether CPEB4 was
involved in miR-1246-induced NSCLC cell migration
and invasion. The miR-1246 inhibitor and siRNAs tar-
geting CPEB4 were co-transfected into A549 cells. The
subsequent transwell assays demonstrated that CPEB4
knockdown partly neutralized the suppressive effects of
the miR-1246 inhibitor on NSCLC cell migration and
invasion (Fig. 4c). These data provided further evidence
that CPEB4 could inhibit miR-1246-induced NSCLC
cell migration and invasion, suggesting that CPEB4 is a
direct and functional target of miR-1246 in NSCLC.
We then evaluated the expression of CPEB4 mRNA in
various lung cancer cell lines (Fig. 4d). The results
showed that the CPEB4 mRNA was inversely correlated
with the expression of miR-1246 in these cell lines
(Fig. 4e and Additional file 1: Figure S1C). To extend
our analysis to clinical cases, we assessed the mRNA
level of CPEB4 in the previous 50 cases of NSCLC and
the adjacent noncancerous lung tissues. CPEB4 mRNA
was downregulated in NSCLC tissues compared with
their respective noncancerous tissues (Fig. 4f ), consist-
ent with the observed CPEB4 protein levels. Moreover,
the expression of CPEB4 was inversely correlated with
the level of miR-1246 in these NSCLC samples (Fig. 4g).
These data suggested that CPEB4 mRNA expression is
negatively correlated with miR-1246 expression in NSCLC.
Discussion
MiRNAs are a class of small, noncoding RNAs which
regulate gene expression by targeting mRNAs for transla-
tional repression or degradation. Accumulating evidence
suggests that deregulation of miRNAs has been frequently
observed in tumor tissues. These miRNAs have regulatory
Table 2 Correlation between CPEB4 expression and different clinicopathological features in NSCLCa
Clinicopathological features No. of cases CPEB4 expression P
High (n, %) Low (n, %)
Age
<60 26 13(50.0 %) 13(50.0 %) 0.496
≥60 24 11(45.8 %) 13(54.2 %)
Gender
Male 22 12(54.5 %) 10(45.5 %) 0.296
Female 28 2(42.9 %) 12(57.1 %)
Histology/differentiation
Well + Moderate 30 14(46.7 %) 16(53.3 %) 0.387
Poor 20 11(55.0 %) 9(45.0 %)
TNM stage
I + II 29 14(48.3 %) 15(51.7 %) 0.312
III + IV 21 12(57.1 %) 9(42.9 %)
aThe median level was used as the cutoff
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roles in the pathogenesis of cancer [24, 25]. Indeed, pa-
tients with lung cancer often exhibit tumor cell invasion
and metastasis before diagnosis, which renders current
treatments, including surgery, radiotherapy, and chemo-
therapy, ineffective. Therefore, studying the molecular
basis of lung cancer is crucial for designing new thera-
peutic agents to improve the survival rate.
In current work, we found that the level of miR-1246
is frequently raised in NSCLC and promotes cell migra-
tion and invasion. CPEB4 serves as the direct miR-1246
target gene and is usually suppressed in NSCLC, and its
expression is correlated with NSCLC patient outcome.
We found that the expression level of miR-1246 in
NSCLC cells is relatively high (Fig. 1). To explore its
functional role, we performed series of assays in NSCLC
cell lines and found that inhibition of miR-1246 in A549
cells significantly reduce migration and invasion. How-
ever, simultaneous reduction in CPEB4 expression re-
verses the effect of miR-1246 inhibition suggesting that
CPEB4 might be a functional target of miR-1246 in
NSCLC. Recent reports also suggested that miR-1246
can enhance cell migration and invasion in hepatocellu-
lar carcinoma (HCC) cells [26] further extending the
oncogenic role of miR-1246. Another recent report on
miR-1246 demonstrated that miR-1246 is a novel target
of p53 transcription factor and its analogue p63/p73 to
suppress the expression of DYRK1A and activate NFAT
both leading to possible tumorigenesis [27]. This finding
further suggested a potential linkage of p53 family with
Down syndrome. Therefore, current knowledge has un-
raveled an oncogenic role of miR-1246 in at least specific
tumors. Further studies are strongly needed to unravel
the hidden layer of complexity about miR-1246 and its
implications in tumorigenesis.
The mechanistic insights into the biological role of
miR-1246 on migration and invasion argued that the tar-
get gene CPEB4 might be implicated. CPEB4 belongs to
the cytoplasmic polyadenylation element-binding protein
family, the members of which primarily modulate transla-
tion by regulating the polyadenylation of target genes. The
CPEB family commonly contains two subfamilies, CPEB1
and CPEB2. Although CPEB1 has been investigated in
depth, the function of CPEB4 which is a member of the
CPEB2 subfamily remains elusive. It was shown that
CPEB4 servers as a pro-survival protein in neurons and
contributes largely meiosis [28, 29]. In pancreatic ductal
cancer and neuroblastoma, CPEB4 is upregulated leading
to the growth and invasion of cancer cells [30]. In current
study, we observed that the levels of CPEB4 were com-
monly down-regulated in NSCLC. The tissue-specific fea-
ture and some other unexplored factors might contribute
to this phenomenon in distinct tumor tissues. Further-
more, we found that knockdown of CPEB4 could promote
the migration and invasion of NSCLC cells. This contra-
diction might be ascribed to the distinct downstream tar-
gets modulated by CPEB4 in different cells because
CPEB4 can alter the translation of numerous genes by dir-
ectly binding to the 3’ UTR [29]. Intriguingly, relatively
high CPEB4 level exhibited a better survival in NSCLC pa-
tients. These results suggested that CPEB4 might act as a
prognostic factor in NSCLC. We also demonstrated that
miR-1246 and CPEB4 expression were inversely correlated
in NSCLC samples suggesting that the downregulation of
CPEB4 may be at least partially due to the upregulation of
miR-1246. Targeting CPEB4 by microRNAs has also been
reported previously [29]. The members of the CPEB2 sub-
family can be controlled by microRNAs through a con-
served sequence in their 3’ UTR [29]. Taken together,
our findings demonstrate that regulation by microRNA
may be a common strategy utilized in CPEB4 regula-
tion. How CPEB4 is involved in the progression of lung
cancer especially the molecular mechanisms demand
in-depth investigation.
Conclusions
In summary, our findings demonstrated that elevated
miR-1246 expression may increase the migratory and in-
vasive potential of NSCLC cells. Knockdown of the miR-
1246 target gene CPEB4 enhanced the migration and
invasion of NSCLC cells. Importantly, CPEB4 expression
is correlated with NSCLC patient outcome. Therefore,
miR-1246/CPEB4 may denote a promising prognostic
and therapeutic target in NSCLC.
(See figure on previous page.)
Fig. 4 CPEB4 suppresses miR-1246-induced migration/invasion and its expression is inversely correlated with miR-1246 in NSCLC. a, b Real-time PCR
and western blot of CPEB4 expression in HEK 293 T cells transfected with siRNAs targeting CPEB4 or a negative control (nc). c Transwell migration and
invasion assays of A549 cells were performed after transfection with a miR-1246 inhibitor, CPEB4 siRNA or a negative control (nc). The protein level of
CPEB4 was detected through western blot. There is statistical significance between group 1 and group 2 as well as between group 2 and group 4. The
results are presented as the mean ± SD. d The relative expression of CPEB4 at the mRNA level was analyzed through real-time PCR (normalized to
β-actin). e The correlation between CPEB4 expression and mature miR-1246 in various lung cancer cell lines was analyzed by linear regression. f The
mRNA level of CPEB4 was determined in 50 pairs of NSCLC tissues and matched noncancerous adjacent lung tissues by real-time PCR. g The
correlation between CPEB4 expression and mature miR-1246 was analyzed in the same NSCLC samples by linear regression. The expression
data were normalized to β-actin and U6 snRNA, respectively. * p < 0.05, ** p < 0.01, *** p < 0.001
Huang et al. Diagnostic Pathology  (2015) 10:127 Page 9 of 10
Additional files
Additional file 1: Figure S1. Transfection efficiency and endogenous
expression of miR-1246. (A) The relative expression level of mature
miR-1246 was determined in A549 and H226 cells infected with
pWPXL-miR-1246 or control lentivirus. U6 snRNA was used as an
internal control. (B) The relative expression of miR-1246 was
determined in A549 and H226 cells infected with miR-1246 inhibitor
or control. (C) The relative expression of miR-1246 in various lung
cancer cells. The relative expression level of mature miR-1246 was
detected by TaqMan real-time PCR. The data were normalized to U6
snRNA. (TIFF 262 kb)
Additional file 2: Figure S2. A miR-1246 mimic facilitates NSCLC cell
migration and invasion in vitro. (A) Transwell migration assays of A549
and H226 cells transfected with the miR-1246 mimic or negative control
(NC). (B) Transwell invasion assays of A549 and H226 cells transfected
with the miR-1246 mimic or NC. The values shown indicate the mean ±
S.E.M. * p < 0.05, ** p < 0.01, *** p < 0.001. (TIFF 1195 kb)
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